Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients With Epidermolysis Bullosa

NCT06594393 is registered in ClinicalTrials.gov with Xinnate AB as lead sponsor.

NCT NCT06594393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06594393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients With Epidermolysis Bullosa
Lead sponsor
Xinnate AB
Phase
Phase 2
Overall status
Recruiting
Start date
January 30, 2026
Completion date
June 30, 2027
Enrollment
32 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

dystrophic epidermolysis bullosa, epidermolysis bullosa (eb), junctional epidermolysis bullosa